Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19

BACKGROUND: Clinical data to support the use of bamlanivimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed. METHODS: 2,335 patients who received single-dose bamlanivimab infusion between November 12, 2020 to February 17, 2021 were compared with a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:medRxiv
Principais autores: Ganesh, Ravindra, Pawlowski, Colin, O’Horo, John C., Arndt, Lori L., Arndt, Richard, Bell, Sarah J., Bierle, Dennis M., Borgen, Molly Destro, Hanson, Sara N., Heyliger, Alexander, Larsen, Jennifer J., Lenehan, Patrick, Orenstein, Robert, Puranik, Arjun, Speicher, Leigh L., Tulledge-Scheitel, Sidna M., Venkatakrishnan, AJ, Wilker, Caroline G., Badley, Andrew D., Razonable, Raymund R.
Formato: Artigo
Idioma:Inglês
Publicado em: Cold Spring Harbor Laboratory 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8168391/
https://ncbi.nlm.nih.gov/pubmed/34075387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.05.23.21257670
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados